bwolfy2002 Monday, 05/25/20 10:53:53 AM Re: hopester post# 80054 Post # of 119164 Ok, so you’re going to take the cash cycle and call it debt, that’s fine. So to be clear it’s not debt used for financing. Ok, so with that they have what about $41MM in “debt”. How many vials sold will cover that? What’s that as a part of their market cap? How many new shares would it take to cover that at today’s price? How much dilution would that be? Until it is no longer a clinical biotech, there will not be sales everyone knows this. One would buy in for the potential for sales. You may sell short hoping it loses, sure, but don’t act like a pre-revenue biotech is failing by not having sales or by having costs to bring the product to market it will one day sell... that’s silly. Let’s leave be for now the fact that this company can save lives. That rooting for it is rooting for humanity. Should make casting shadows seem less enjoyable I would think. I’m often wrong about human nature, but as far as the company and my investment in it, everything is has been A ok.